PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Korea Post-marketing Surveillance for Xeljanz (Registered) in Ulcerative Colitis Patients
- Conditions
- Ulcerative Colitis
- First Posted Date
- 2019-08-28
- Last Posted Date
- 2022-11-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 110
- Registration Number
- NCT04071405
- Locations
- 🇰🇷
Pfizer, Seoul, Korea, Republic of
Study of Commercial and Phase 3 of PF-04965842 Formulations, Estimation of Effect of Food on Commercial Formulation
- Conditions
- Dermatitis, Atopic
- Interventions
- Drug: P3-FastDrug: Comm-FastDrug: Vari-FastDrug: Comm-Fed
- First Posted Date
- 2019-08-22
- Last Posted Date
- 2020-01-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 46
- Registration Number
- NCT04065633
- Locations
- 🇺🇸
New Haven Clinical Research Unit, New Haven, Connecticut, United States
Pharmacokinetics and Safety of RV521 Formulations
- First Posted Date
- 2019-08-22
- Last Posted Date
- 2024-06-07
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 9
- Registration Number
- NCT04065698
- Locations
- 🇬🇧
Richmond Pharmacology Ltd, London, United Kingdom
Avelumab With Bempegaldesleukin With or Without Talazoparib or Enzalutamide in Advanced or Metastatic Solid Tumors
- Conditions
- Squamous Cell Carcinoma of the Head and Neck (SCCHN)Metastatic Castration Resistant Prostate Cancer (mCRPC)
- Interventions
- First Posted Date
- 2019-08-09
- Last Posted Date
- 2021-10-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 3
- Registration Number
- NCT04052204
- Locations
- 🇺🇸
University of Rochester Medical Center, Rochester, New York, United States
🇪🇸Hospital Universitari Vall d'Hebron, Barcelona, Spain
🇧🇪GZA Ziekenhuizen campus Sint-Augustinus, Wilrijk, Antwerpen, Belgium
A Study to Evaluate Patient Characteristics and Treatment Patterns Among Rheumatoid Arthritis Patients
- Conditions
- Rheumatoid Arthritis
- First Posted Date
- 2019-08-06
- Last Posted Date
- 2023-06-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1349
- Registration Number
- NCT04047121
- Locations
- 🇺🇸
Pfizer, Collegeville, Pennsylvania, United States
Relative Bioavailability Study of a Modified-Release Formulation of PF-06865571 in Healthy Adult Participants
- Conditions
- Healthy Participants
- Interventions
- Drug: PF-06865571 400 mg Immediate Release (IR) in Fed StateDrug: PF-06865571 50 mg Modified Release (MR) in Fed StateDrug: PF-06865571 400 mg MR in Fed StateDrug: PF-06865571 400 mg MR in Fasted State
- First Posted Date
- 2019-08-02
- Last Posted Date
- 2019-11-27
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT04044053
- Locations
- 🇧🇪
Brussels Clinical Research Unit, Brussels, Be-bru, Belgium
Single-dose PK Study of Ceftazidime-Avibactam In Hospitalized Children Receiving Systemic Antibiotics for Nosocomial Pneumonia
- Conditions
- Hospitalized Children With Suspected or Confirmed Nosocomial Pneumonia
- Interventions
- Drug: Ceftazidime-avibactam
- First Posted Date
- 2019-08-01
- Last Posted Date
- 2022-09-09
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 4
- Registration Number
- NCT04040621
- Locations
- 🇨🇳
Chang Gung Memorial Hospital-Linkou, Taoyuan City, Taiwan
🇨🇳Taipei Municipal Wanfang Hospital, Taipei, Taiwan
🇨🇳Chengdu Women's and Children's Central Hospital, Chengdu, Sichuan, China
A Study to Evaluate Long-Term Maintenance Treatment With Once Daily Crisaborole Ointment 2% in Pediatric and Adult Participants With Mild-to-Moderate Atopic Dermatitis
- First Posted Date
- 2019-07-31
- Last Posted Date
- 2023-03-08
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 620
- Registration Number
- NCT04040192
- Locations
- 🇺🇸
Skin Care Research LLC, Boca Raton, Florida, United States
🇮🇱The Chaim Sheba Medical Center, Ramat - Gan, Israel
🇺🇸Colorado Springs Dermatology Clinic, PC, Colorado Springs, Colorado, United States
Precedex Special Investigation (in Pediatric Patients)
- First Posted Date
- 2019-07-31
- Last Posted Date
- 2024-02-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 111
- Registration Number
- NCT04040439
- Locations
- 🇯🇵
Pfizer Japan Local Country Office, Tokyo, Japan
A Renal Impairment Study for PF-06651600
- First Posted Date
- 2019-07-30
- Last Posted Date
- 2021-05-18
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 8
- Registration Number
- NCT04037865
- Locations
- 🇺🇸
Investigational Drug Services (IDS) University of Miami Hospitals and Clinics, Miami, Florida, United States
🇺🇸University of Miami Division of Clinical Pharmacology, Miami, Florida, United States
🇺🇸Prism Clinical Research, LLC, Saint Paul, Minnesota, United States